Cutaneous Lupus Erythematosus Clinical Trial
Official title:
Randomized, Double-blind, Placebo Controlled, Proof of Concept Study Assessing the Efficacy and Safety of the RIPK1-inhibitor SAR443122 in Patients With Moderate to Severe Subacute or Discoid/Chronic Cutaneous Lupus Erythematosus
Primary Objective: - Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE) Secondary Objectives: - Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity) - Assess the effect of SAR443122 on CLE induced itch and overall pain - Assess the effect of SAR443122 on the proportion of disease activity responders compared to placebo - Assess the effect of SAR443122 on the CLASI components score - Assess the effect of SAR443122 on the Investigator's global assessment for CLE (IGA-CLE) - Assess oral cavities for patients with oral lesions - Assess the disease specific quality of life (QoL) - Assess the safety and tolerability of SAR443122 in patients with CLE - Assess the pharmacokinetics (PK) exposure of SAR443122 in patients with CLE
Total study duration per participant will be up 20 weeks including: - A screening period of up to 4 weeks - A treatment period of 12 weeks - A post treatment follow-up period of 4 weeks ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01776190 -
Low-dose UVA1 Radiation in Cutaneous Lupus Patients
|
N/A | |
| Completed |
NCT00420173 -
Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)
|
N/A | |
| Terminated |
NCT04809623 -
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
|
Phase 1 | |
| Completed |
NCT01300208 -
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
|
Phase 2 | |
| Terminated |
NCT01470313 -
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
|
Phase 1 | |
| Completed |
NCT01146444 -
Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)
|
N/A | |
| Completed |
NCT03134222 -
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
|
Phase 2 | |
| Completed |
NCT01629784 -
Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus
|
N/A | |
| Completed |
NCT00470912 -
Sunscreen RV 2457C in Photoinduced CLE
|
Phase 3 | |
| Completed |
NCT01841619 -
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
|
Phase 0 | |
| Completed |
NCT00523588 -
Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser
|
Phase 2 | |
| Recruiting |
NCT06411106 -
Deep Phenotyping of Cutaneous Lupus Erythematosus
|
N/A | |
| Not yet recruiting |
NCT06015737 -
A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
|
Phase 3 | |
| Terminated |
NCT01498406 -
Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus
|
Phase 2 | |
| Completed |
NCT04647708 -
Study of M5049 in CLE and SLE Participants
|
Phase 1 | |
| Completed |
NCT03817424 -
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
|
Phase 1 | |
| Active, not recruiting |
NCT03260166 -
Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT00317681 -
Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)
|
Phase 2 |